Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Rheumatology

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 9375862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid.

  1995cited by this paper
• Soluble interleukin‐6 (IL‐6) receptor augments central effects of IL‐6 in vivo

  1995cited by this paper
• Evaluation of soluble IL‐6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases

  1995cited by this paper
• Soluble receptors for cytokines and growth factors: generation and biological function.

  1994cited by this paper
• Soluble interleukin 6 receptor in biological fluids from human origin.

  1994cited by this paper
• Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis.

  1994cited by this paper
• Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors.

  1994cited by this paper
• Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

  1994cited by this paper
• Oncostatin M stimulates proliferation in B9 hybridoma cells: potential role of oncostatin M in plasmacytoma development.

  1994cited by this paper
• IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells.

  1994cited by this paper
• Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy.

  1994cited by this paper
• Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy

  1993cited by this paper
• Soluble tumor necrosis factor receptors in human inflammatory synovial fluids.

  1993cited by this paper
• Interleukin-6 in biology and medicine.

  1993cited by this paper
• Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

  1993cited by this paper
• Responsiveness of the interleukin (IL)-6-dependent cell line B9 to IL-11.

  1993cited by this paper
• The soluble interleukin‐6 receptor is generated by shedding

  1993cited by this paper
• Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo.

  1992cited by this paper
• Cytokine inter-relationships and their association with disease activity in arthritis.

  1992cited by this paper
• Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.

  1992cited by this paper
• Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

  1992cited by this paper
• Relationships between local inflammation, interleukin‐6 concentration and the acute phase protein response in arthritis patients

  1991cited by this paper
• Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins

  1991cited by this paper
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper
• IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

  1989cited by this paper
• Interleukin-6 in synovial fluid from patients with arthritis.

  1989cited by this paper
• Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases.

  1988cited by this paper
• Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.

  1988cited by this paper
• Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor

  1987cited by this paper
• Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

  1987cited by this paper
• False positive immunometric assays caused by anti-immunoglobulin antibodies: a case report.

  1985cited by this paper
• Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

  1985cited by this paper

• Contemporary approaches to the management of rheumatoid arthritis: precision and progress.

  2025cites this paper
• Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review

  2024cites this paper
• Replenishing decoy extracellular vesicles inhibits phenotype remodeling of tissue-resident cells in inflammation-driven arthritis

  2023cites this paper
• Reumatología

  2023cites this paper
• CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6/JAK1/STAT3 Signaling in Rheumatoid Arthritis

  2021cites this paper
• Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab

  2019cites this paper
• TGF-β dampens IL-6 signaling in articular chondrocytes by decreasing IL-6 receptor expression.

  2019cites this paper
• Endogenous stimulation is responsible for the high frequency of IL-17A-producing neutrophils in patients with rheumatoid arthritis

  2019cites this paper
• Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib

  2019cites this paper
• Family-based analyses reveal novel genetic overlap between cytokine interleukin-8 and risk for suicide attempt.

  2019cites this paper
• Cytokine targeting in rheumatoid arthritis.

  2019cites this paper
• Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study

  2018cites this paper
• Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018

  2018cites this paper
• The role of sIL-6R mediated trans-signaling in cardiovascular morbidity in Rheumatoid Arthritis

  2018cites this paper
• Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

  2017cites this paper
• Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy

  2017cites this paper
• Infrapatellar fat pad aggravates degeneration of acute traumatized cartilage: a possible role for interleukin-6.

  2017cites this paper
• Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.

  2017cites this paper
• RÔLE DE POLYMORPHISMES NUCLÉOTIDIQUES DANS LES GÈNESDE L’INTERLEUKINE-4 ET SON RÉCEPTEUR ET DU CORÉCEPTEURCD40, ET DES ALLÈLES HLA-DR, DANS LA PROGRESSION DE LAPOLYARTHRITE INFLAMMATOIRE D’INSTALLATION RÉCENTE

  2017cites this paper
• B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

  2017cites this paper
• Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

  2017cites this paper
• Anti-inflammatory Effect of Methyl Gallate on Experimental Arthritis: Inhibition of Neutrophil Recruitment, Production of Inflammatory Mediators, and Activation of Macrophages.

  2016cites this paper
• The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity.

  2016cites this paper
• The involvement of follistatin-like protein 1 in osteoarthritis by elevating NF-κB-mediated inflammatory cytokines and enhancing fibroblast like synoviocyte proliferation

  2015cites this paper
• Integrated analysis of mRNA and miRNA expression in response to interleukin-6 in hepatocytes.

  2015cites this paper
• Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.

  2015cites this paper
• Cytosolic Phospholipase A2 Modulates TLR2 Signaling in Synoviocytes

  2015cites this paper
• Expression of Semaphorin 4A and its potential role in rheumatoid arthritis

  2015cites this paper
• Dynamics of Combined Oral Contraceptive: A Study of Some Cytokines in Female Wistar Rats

  2015cites this paper
• Molecular mechanisms of inflammation – a central role for cytosolic phospholipase A2

  2014cites this paper
• Alternative Intronic Polyadenylation Generates the Interleukin-6 Trans-signaling Inhibitor sgp130-E10*

  2014cites this paper
• Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour

  2014cites this paper
• Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis

  2014cites this paper
• Estradiol-potentiated cadherin-11 in synovial membrane involves in temporomandibular joint inflammation in rats.

  2014cites this paper
• [Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

  2014cites this paper
• Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

  2013cites this paper
• Increased levels of interleukin-6 in synovial lavage fluid from patients with mandibular condyle fractures: correlation with magnetic resonance evidence of joint effusion.

  2013cites this paper
• 5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway.

  2013cites this paper
• Leptin stimulates interleukin-6 production via janus kinase 2/signal transducer and activator of transcription 3 in rheumatoid synovial fibroblasts.

  2013cites this paper
• Altered Bone Resorption In Type 1 And Type 2 Diabetes

  2012cites this paper
• Interleukin‐6 upregulates expression of ADAMTS‐4 in fibroblast‐like synoviocytes from patients with rheumatoid arthritis

  2012cites this paper
• Interstitial granulomatous dermatitis with arthritis responding to tocilizumab.

  2012cites this paper
• A woman with rheumatoid arthritis, Sjögren's Syndrome, leg ulcer, and significant weight loss

  2012cites this paper
• CTGF Increases IL-6 Expression in Human Synovial Fibroblasts through Integrin-Dependent Signaling Pathway

  2012cites this paper
• Biology of interleukin-6 production by human natural killer cells

  2012cites this paper
• The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors

  2011cites this paper
• Beta2-microglobulina en líquido cefalorraquídeo de recién nacidos con infección congénita sintomática por citomegalovirus: Un indicador certero de la gravedad de la afectación del sistema nervioso central

  2011cites this paper
• Erythematous patches and plaques on the chest with induration of the breasts. Metastatic papillary RCC in dermal lymphatics.

  2011cites this paper
• Tocilizumab for the Treatment of Adults with Moderate to Severe Rheumatoid Arthritis

  2011cites this paper
• Cadherin-11 regulates fibroblast inflammation

  2011cites this paper
• Serum estrogen and interleukin-6 levels in postmenopausal female osteoarthritis patients.

  2011cites this paper
• Cytokine profiles in localized scleroderma and relationship to clinical features.

  2011cites this paper
• New biologics for rheumatoid arthritis.

  2011cites this paper
• Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity

  2011cites this paper
• Overnight variations in IL-6 in synovial fluid and plasma in patients with active rheumatoid arthritis

  2010cites this paper
• Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010)

  2010cites this paper
• gp130 at the nexus of inflammation, autoimmunity, and cancer

  2010cites this paper
• Fibroblast‐like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin‐11

  2010cites this paper
• Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?

  2010cites this paper
• Effect of Yeast Superoxide Dismutase Treatment on Some Mediators of Infl ammation during Adjuvant-Induced Arthritis in Mice

  2010cites this paper
• The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis

  2010cites this paper
• Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease

  2009cites this paper
• Polimorfismos genéticos y farmacogenética en la artritis reumatoide

  2009cites this paper
• Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis

  2009cites this paper
• [Gene polymorphisms and pharmacogenetics in Rheumatoid Arthritis].

  2009cites this paper
• Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis

  2008cites this paper
• Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

  2008cites this paper
• Neutrophil-related immunoinflammatory disturbance in steroid-overdosed ulcerative colitis patients

  2008cites this paper
• Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model.

  2008cites this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cites this paper
• Inhibiting interleukin-6 in rheumatoid arthritis

  2008cites this paper
• Interleukin-6 and tumor necrosis factor alpha levels in the serum and synovial fluid in relation to bone mineral density and turnover in children with juvenile idiopathic arthritis

  2008cites this paper
• Angiogenesis in the inflammation of arthritis

  2008cites this paper
• Castleman disease IL-6 receptor antibody , tocilizumab , in patients with rheumatoid − anti interleukin-6 ( IL-6 ) and soluble IL-6 receptor after administration of an Mechanisms and pathologic significances in increase in serum

  2008cites this paper
• Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis.

  2007cites this paper
• Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis.

  2007cites this paper
• The human synovial fluid proteome: A key factor in the pathology of joint disease

  2007cites this paper
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  2007cites this paper
• Enhancement of anti-inflammatory tendency by SB203580, p38α specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A

  2006cites this paper
• Beta2-microglobulin concentrations in cerebrospinal fluid correlate with neuroimaging findings in newborns with symptomatic congenital cytomegalovirus infection

  2006cites this paper
• IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis.

  2005cites this paper
• Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes.

  2005cites this paper
• New Biochemical Insights into the Pathogenesis of Osteoarthritis and the Role of Laboratory Investigations in Clinical Assessment

  2005cites this paper
• Norepinephrine in mice inhibits secretion of splenic IL-6 during the dark period but stimulates its secretion in the light period--possible role of the corticosterone tone.

  2005cites this paper
• Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan

  2005cites this paper
• Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis.

  2005cites this paper
• Osteoarthritis, angiogenesis and inflammation.

  2005cites this paper
• Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts.

  2005cites this paper
• Is IL-6 a therapeutic target?

  2004cites this paper
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cites this paper
• Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice.

  2004cites this paper
• Clinical experience with inhibition of interleukin-6.

  2004cites this paper
• Lipoxin A4 Counteracts Synergistic Activation of Human Fibroblast-like Synoviocytes

  2004cites this paper
• Nutritional status and cytokine‐related protein breakdown in elderly patients with gastrointestinal malignancies

  2004cites this paper
• Inflammatory markers and physical function among older adults with knee osteoarthritis.

  2004cites this paper
• Inflammation-responsive promoters for fine-tuned gene therapy in rheumatoid arthritis.

  2004cites this paper
• A case of pachydermoperiostosis associated with arthritis

  2003cites this paper
• Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.

  2003cites this paper
• Allogenic blood transfusion is an independent risk factor for infective complications after less invasive gastrointestinal surgery.

  2003cites this paper
• Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

  2003cites this paper